# Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome

> **NCT01714011** · PHASE4 · COMPLETED · sponsor: **University of Malaya** · enrollment: 175 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Ziprasidone
- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT01714011
- **Lead sponsor:** University of Malaya
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2012-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01714011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01714011, "Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01714011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*